Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Is Epilepsy Surgery on the Decline?

    Is Epilepsy Surgery on the Decline?

    August 1, 2014
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Rolandic Epilepsy Surgery — Weighing the Risks

    The Value of MEG in Evaluating Patients for Epilepsy Surgery

    The Effect of Epilepsy on Patient Mortality: A Dutch Cohort Study with 40 Years

    Keywords

    Neurology

    ABSTRACT & COMMENTARY

    Is Epilepsy Surgery on the Decline?

    By Padmaja Kandula, MD

    Assistant Professor of Neurology, Comprehensive Epilepsy Center, Weill Cornell Medical College

    Dr. Kandula reports no financial relationships relevant to this field of study.

    SYNOPSIS: In this 20-year, retrospective study, the authors summarize surgical trends in three major German epilepsy centers and identified a declining prevalence of epilepsy surgery from 1998 to 2008.

    SOURCE: Helmstaedter C, et al. Temporal lobe surgery in Germany from 1988 to 2008: Diverse trends in etiological subgroups. Europ J Neurol 2014;21:827-834.

    Despite class I evidence and subsequent 2013 American Academy of Neurology (AAN) Practice Guidelines advocating early surgery in drug-resistant epilepsy (failure of two anti-epileptic agents), surgery for epilepsy has not increased in the United States over the last two decades. In this present retrospective study, the authors parallel the U.S. experience and summarize the experience of surgical trends in three major German epilepsy centers from 1988 to 2008. In contrast to previous papers, however, surgical trends with regards to other temporal lobe etiologies are taken into consideration.

    In total, 2812 patients with temporal lobe epilepsy (TLE) underwent epilepsy surgery in all three centers combined. The authors addressed the number of surgeries over time, duration of epilepsy before surgical intervention, differences in trends between etiologic categories of TLE, and inter-institution variability.

    Not surprisingly, with the advent of improved MRI technique, there was a steady increase in epilepsy surgeries for each 4-year epoch from 1988 to 2004, from 296 in the early epoch to more than 700 patients more recently. Correspondingly, there was an increase in patients with hippocampal sclerosis from 30-58% during the years of 1988-2004, with a subsequent plateau in the years thereafter. From 2005 to 2008, there was a subsequent decrease to 600 epilepsy surgeries with relative stability in the prevalence of hippocampal sclerosis (58%).

    An interesting observation was the longer duration of epilepsy in patients with hippocampal sclerosis compared to other TLE etiologic subtypes, such as tumors, vascular lesions, and focal cortical dysplasia. In fact, the group with hippocampal sclerosis had continuously increasing age at time of surgery by an average of 7 years over the observed two decades.

    COMMENTARY

    The steady increase of patients with reported hippocampal sclerosis undergoing epilepsy surgery is not surprising. However, the overall decline in epilepsy surgeries with relative stability of the hippocampal sclerosis rate, from 2005-2008, is perplexing. In all three centers, there was a notable trend of increasing age at surgical intervention and increasing duration of epilepsy with an overall fixed rate of hippocampal sclerosis from 2005-2008. Various theories have been proposed to explain this inconsistency. One plausible explanation is the influence of disease-modifying factors such as aggressive treatment of brain infections, febrile seizures, and the advent of second- and third-generation anti-epileptic agents. Although the idea of influencing the natural course of hippocampal sclerosis via better medical care and aggressive pharmacologic treatment is satisfying, without larger population-based studies, no definitive conclusions can be drawn. Resective surgery is well established for the treatment of TLE, but the future of epilepsy treatment is evolving. Currently neuro-stimulatory treatment is in its infancy, but perhaps the nature of this discussion will become even more varied and intricate over the next two decades with a growing arsenal of treatment options.

    Pharmacology Watch, Clinical Briefs Available Online

    The August 2014 issues of Pharmacology Watch and Clinical Briefs in Primary Care are now available exclusively by e-mail or online. You can access these two valuable supplements to Neurology Alert at http://www.reliasmedia.com/supplements/. We will send PDF copies of these supplements to you by e-mail if you prefer. Please send an e-mail with your name and/or subscriber number to customerservice@ahcmedia.com with Digital AHC Supplements in the subject line. We welcome your feedback and appreciate your continued support as a subscriber to Neurology Alert.

     

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert 2014-08-01
    August 1, 2014

    Table Of Contents

    Is Stem Cell Transplantation a Viable Treatment Option for CIDP?

    OnabotulinumtoxinA for Treatment of Chronic Migraines

    Diffusion Tensor MRI Advances Diagnostic Accuracy in ALS

    The Neurophysiological Features of Myoclonus-Dystonia

    Is Epilepsy Surgery on the Decline?

    Atrial Fibrillation and Cryptogenic Stroke: Important New Information

    Begin Test
    Buy this Issue/Course

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2021 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing